Five-Year Follow-Up Data for SPRYCEL® (dasatinib) 100 mg Once Daily

Sat, 11/06/2011 - 3:13pm

Five-Year Follow-Up Data for SPRYCEL® (dasatinib) 100 mg Once Daily Demonstrated 78 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant or Intolerant to Gleevec®*

http://www.businesswire.com/news/home/20110603005852/en/Five-Year-Follow...®-dasatinib-100-mg

ian hinley

In reply to ian hinley

Sat, 11/06/2011 - 3:15pm

http://www.businesswire.com/news/home/20110603005852/en/Five-Year-Follow-Up-Data-SPRYCEL®-dasatinib-100-mg

You are here

Five-Year Follow-Up Data for SPRYCEL® (dasatinib) 100 mg Once Daily